Galectin Therapeutics Inc. Enters into Material Definitive Agreement for Line of Credit

Galectin Therapeutics Inc. has entered into a Line of Credit Letter Agreement with Richard E. Uihlein, establishing a supplemental line of credit of up to $10.00 million. This credit line is intended to finance the company's working capital needs and can be drawn upon through January 31, 2027. Advances will be evidenced by unsecured, convertible promissory notes with an interest rate of the Applicable Federal Rate plus 2%, due by June 30, 2027. The notes are convertible into the company's common stock at the closing price on the date of the note, but not less than the closing price on December 19, 2025. In connection with this agreement, the company will issue warrants to purchase up to 200,000 shares of common stock, with exercise prices set at 150% of the closing price on the date of the promissory note, subject to a maximum of $10.00 and a minimum of the closing price on December 19, 2025. These warrants expire on December 31, 2029. The agreement also includes provisions for registration rights for shares issued upon conversion or exercise.